# Cancilico

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cancilico

- Industry: Biotechnology
- Headquarters: Dresden, Germany
- Website: www.cancilico.com
- Total disclosed funding: $2.9M
- Latest round: Seed (Dec 11, 2025)
- Investors on record: 3

## About

Based in Germany, Cancilico GmbH specializes in AI-powered diagnostic solutions, particularly focused on automating the analysis of bone marrow samples to enhance efficiency and accuracy in hematological assessments.Founded in 2023 in Dresden, Germany, Cancilico GmbH focuses on the development of AI-driven diagnostic tools. The company has successfully completed a SEED funding round, raising EUR 2.5 million, co-led by High-Tech Gruenderfonds, Technologiegruenderfonds Sachsen, and GEDAD GmbH, with the latest round finalized on January 20, 2026. This recent funding round marks the company's first significant funding effort, consolidating its operational foundation.Cancilico specializes in AI-powered diagnostic solutions, with MyeloAID as its flagship product. MyeloAID automates the classification and counting of cells in bone marrow samples, leveraging advanced AI algorithms for rapid and precise analyses. It allows users to generate detailed myelograms in minutes, enhancing diagnostic accuracy and efficiency. The primary customers include healthcare providers, laboratories, and medical researchers focused on blood cancer diagnostics, and the company markets its products across Europe and North America.Cancilico's revenue model is based on subscription services and partnerships with healthcare institutions and laboratories that require advanced diagnostic tools. Clients typically engage through contracts that integrate MyeloAID within their laboratory systems, allowing for scalable solutions tailored to various facility sizes. Revenue is generated through annual fees and licensing costs for MyeloAID and related AI services, ensuring alignment with evolving medical research demands.Following the recent SEED funding of EUR 2.5 million raised in January 2026, Cancilico GmbH plans to enhance its AI bone marrow diagnostic tools, support clinical validation, and expand research into digital biomarkers. The company aims to launch new products in the coming year while targeting expansion into new geographic markets, including Asia and Latin America, by 2028.

## Funding rounds

- Seed, Dec 11, 2025, $2.9M — High-Tech Gruenderfonds, Technologiegruenderfonds Sachsen, GEDAD

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed
- Technologiegruenderfonds Sachsen — Seed
- GEDAD — Seed